Art. -Nr.: HY-13768A

Topotecan hydrochloride

Name: Topotecan hydrochloride
Brand: MedChemExpress
SKU: HY-13768A
Price: 38.00 USD
Availability: InStock
Rating: 5 (40 reviews)

(Synonyms: SKF 104864A hydrochloride; NSC 609669 hydrochloride)

40 Cited Publications

Kundenbewertung

Based on 40 publication(s) in Google Scholar

Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.79%
CAS. Nr.: 119413-54-6
Formel: C₂₃H₂₄ClN₃O₅
Molecular Weight:457.91

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light)

Topotecan hydrochloride Chemical Structure

CAS. Nr.: 119413-54-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (40)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.

IC₅₀ & Target

^[1]

Topoisomerase I

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.162 μM Compound: Topotecan	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 24980118]
Bel-7402	IC₅₀	0.4 μg/mL Compound: Topotecan	In vitro cytotoxicity against Bel7402 cell line (human liver cancer) using MTT assay In vitro cytotoxicity against Bel7402 cell line (human liver cancer) using MTT assay	[PMID: 15225719]
Caco-2	IC₅₀	0.119 μM Compound: Topotecan	Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay	[PMID: 24980118]
HCT-8	IC₅₀	0.03 μg/mL Compound: Topotecan	In vitro cytotoxicity against HCT-8 cell line (human colon cancer) using MTT assay In vitro cytotoxicity against HCT-8 cell line (human colon cancer) using MTT assay	[PMID: 15225719]
HCT-8	IC₅₀	1.875 μM Compound: 3, Topotecan	Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HeLa	IC₅₀	0.38 μM Compound: Topotecan	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 24980118]
HepG2	IC₅₀	4.208 μM Compound: 3, Topotecan	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
Jurkat	IC₅₀	0.127 μM Compound: Topotecan	Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay	[PMID: 24980118]
KB	IC₅₀	0.02 μg/mL Compound: Topotecan	In vitro cytotoxicity against KB cell line (human epidermoid carcinoma of the nasopharynx) using MTT assay In vitro cytotoxicity against KB cell line (human epidermoid carcinoma of the nasopharynx) using MTT assay	[PMID: 15225719]
KB	IC₅₀	2.282 μM Compound: 3, Topotecan	Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay	[PMID: 25481395]
MDA-MB-231	IC₅₀	0.473 μM Compound: Topotecan	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24980118]
NCI-H460	IC₅₀	0.61 μM Compound: 2	Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium	[PMID: 19530720]
SGC-7901	IC₅₀	2.292 μM Compound: 3, Topotecan	Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay	[PMID: 25481395]

In Vitro

Topotecan Hydrochloride (SKF 104864A Hydrochloride) obviously inhibits the proliferation of not only human glioma cells but also glioma stem cells (GSCs) in a dose- and time-dependent manner. According to the IC₅₀ values at 24 h, 3 μM of Topotecan Hydrochloride is selected as the optimal administration concentration. In addition, Topotecan Hydrochloride induces cell cycle arrest in G0/G1 and S phases and promoted apoptosis. Results show that cell viability is inhibited by Topotecan Hydrochloride in a dose-dependent manner. 2, 20 and 40 μM of Topotecan Hydrochloride obviously inhibits the cell viability compared with the control groups. The IC₅₀ values of Topotecan Hydrochloride at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87. Thus 3 μM of Topotecan Hydrochloride is selected as the optimal administration concentration in the subsequent experiments^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NUB-7 metastatic model, the animals belonging to all the 4 groups are sacrificed after 14 days of treatment. Compared with the control, Low dose metronomic (LDM) Topotecan Hydrochloride and TP+Pazopanib (PZ) liver weights are significantly lower in TP+PZ-treated animals, compared with PZ. Microscopic tumors are visible in the livers of mice belonging to all the groups except TP+PZ confirming the ability of Topotecan Hydrochloride+PZ to control liver metastasis. In a previous dose-response study, the daily dose of oral metronomic Topotecan Hydrochloride (0.5, 1.0, and 1.5 mg/kg) causes greater reduction in microvascular density compared with weekly maximum-tolerated dose regimen (7.5 and 15 mg/kg) in an ovarian cancer model, but the mice treated with 1.5 mg/kg daily, oral Topotecan Hydrochloride show decreased food intake, and a lesser antitumor effect^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 119413-54-6
Appearance Solid
Molecular Weight 457.91
Formel C₂₃H₂₄ClN₃O₅
Color Yellow to orange
SMILES

[H]Cl.O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O
Synonyms

SKF 104864A hydrochloride; NSC 609669 hydrochloride
Structure Classification
- Alkaloids
- Quinoline Alkaloids
- Phenols
- Monophenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light)

Publications (40)

All In Vivo Efficacy StudyFlow CytometryCell Proliferation/Viability AssayIFWB

Sort by:

Journal Impact Factor

Cancer Res

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality. [Abstract]

2023 Dec 15;83(24):4015-4029. PMID: 37987734

Topotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Dec 15;83(24):4015-4029. [Abstract]

Topotecan hydrochloride (10 mg/kg; ip). Tumor weights from 10A.PM xenografts after Topotecan treatment.
J Extracell Vesicles

Analysis of extracellular vesicle DNA at the single-vesicle level by nano-flow cytometry. [Abstract]

2022 Apr;11(4):e12206. PMID: 35373518

Topotecan hydrochloride purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2022 Apr;11(4):e12206. [Abstract]

Topotecan hydrochloride (20 μM; 48 h). Bivariate dot‐plots of SYTO 16 fluorescence versus EV size of EVs for EV preparations from HCT‐15 cells treated with DMSO control (i), etoposide (ii), SN‐38 (iii) or topotecan (iv).
Nat Commun

Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death. [Abstract]

2025 Jun 2;16(1):5126. PMID: 40456709
Nat Commun

Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]

2019 Aug 21;10(1):3761. PMID: 31434880

Topotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

Topotecan (10 mg/kg; Intraperitoneal injection). Representative images and the apoptotic rate the indicated chemotherapy-treated xenograft tumors.

Topotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

Topotecan (10 mg/kg; Intraperitoneal injection). IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.
J Exp Clin Cancer Res

Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. [Abstract]

2018 Dec 20;37(1):321. PMID: 30572915
Adv Sci (Weinh)

TME/NIR Dual-Responsive Zinc-Based Targeted Nanoagonist for Multimodal Amplification of STING-Mediated Cancer Immunotherapy. [Abstract]

2026 Jun 9:e23182. PMID: 42261811
MedComm (2020)

KSQ-4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1-Mediated Multidrug Resistant Cancers. [Abstract]

2025 Nov 29;6(12):e70517. PMID: 41328326
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Cell Death Dis

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis. [Abstract]

2024 Jan 18;15(1):66. PMID: 38238307
Cell Commun Signal

BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. [Abstract]

2024 Jun 13;22(1):325. PMID: 38872211
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
NPJ Precis Oncol

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. [Abstract]

2024 Jun 5;8(1):128. PMID: 38839871

Topotecan hydrochloride purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2024 Jun 5;8(1):128. [Abstract]

Topotecan hydrochloride (0.0001-100 μM; 48 h). Dose-response curves after various concentrations of chemotherapeutic drugs in DYRK1A-KOs and NT-KOs for HCT-116 cell.
J Transl Med

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. [Abstract]

2024 Aug 14;22(1):766. PMID: 39143619
Cancer Immunol Res

Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]

2023 May 3;11(5):583-599. PMID: 36921097
Cell Rep

Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]

2025 Mar 25;44(4):115466. PMID: 40138312
Cell Rep

miR-449a/miR-340 reprogram cell identity and metabolism in fusion-negative rhabdomyosarcoma. [Abstract]

2025 Jan 11;44(1):115171. PMID: 39799567
Mol Cancer Ther

2026 Jul 15:10.1158/1535-7163.MCT-26-0182. PMID: 42456172
Pharmaceutics

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. [Abstract]

2022 Nov 24;14(12):2595. PMID: 36559089
Eur J Med Chem

Innovative medicinal chemistry strategies for enhancing drug solubility. [Abstract]

2024 Dec 5:279:116842. PMID: 39260319
Biochem Pharmacol

Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo. [Abstract]

2023 Oct:216:115769. PMID: 37634597
J Biomed Inform

From Centralized to Ad-Hoc Knowledge Base Construction for Hypotheses Generation. [Abstract]

2023 Jun:142:104383. PMID: 37196989
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Int J Mol Sci

Inhibition of ABCG2 by SCO-101 Enhances Chemotherapy Efficacy in Cancer. [Abstract]

2025 Apr 17;26(8):3790. PMID: 40332396
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Sci Rep

Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. [Abstract]

2019 Oct 22;9(1):15099. PMID: 31641154
Cancers (Basel)

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells. [Abstract]

2021 Dec 31;14(1):193. PMID: 35008354
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
J Virol

Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. [Abstract]

2019 May 15;93(11):e02230-18. PMID: 30867306
J Immunol

Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation. [Abstract]

2022 Jul 1;209(1):171-179. PMID: 35725272
J Nat Prod

Ingenane Diterpenoids from Euphorbia peplus as Potential New CHK1 Inhibitors That Sensitize Cancer Cells to Chemotherapy. [Abstract]

2025 Mar 28;88(3):688-705. PMID: 40056138
Phytochemistry

Spectanoids A-H: Eight undescribed sesterterpenoids from Aspergillus spectabilis. [Abstract]

2021 Nov:191:112910. PMID: 34481345
FASEB Bioadv

Effect of static magnetic field on DNA synthesis: The interplay between DNA chirality and magnetic field left-right asymmetry. [Abstract]

2020 Mar 7;2(4):254-263. PMID: 32259051
bioRxiv

2026 Mar 13.
bioRxiv

2025 Sep 21.
Indiana University Indianapolis

2025.
bioRxiv

Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]

2024 Jul 7:2024.07.04.601620. PMID: 39372755
bioRxiv

2023 Apr 14.
Universitat Autònoma de Barcelona

2022 Aug.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (218.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 33.33 mg/mL (72.79 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1838 mL

10.9192 mL

21.8384 mL

5 mM

0.4368 mL

2.1838 mL

4.3677 mL

10 mM

0.2184 mL

1.0919 mL

2.1838 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Cell Assay^[1]

The U251, U87, GSCs-U251 and GSCs-U87 cells are seeded at a density of 2×10⁴ cells per well in 96-well plates separately, and incubated for 24 h. Cells are administered with Shikonin and Topotecan Hydrochloride (0.02, 0.2, 2, 20, 40 μM). After the treatment, 10 μL of cell counting kit-8 (CCK-8) is added into each well for additional 1-hour incubation at 37°C. The optical density (OD) is read with a microplate reader at 450 nm^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
For subcutaneous xenograft studies, we used SK-N-BE, SH-SY5Y, KHOS, and RH30. 1×10⁶ cells are implanted subcutaneously into the inguinal fat pad of each of nonobese diabetic/severe combined immune deficient (NOD/SCID) mice. When tumors reached 0.5 cm in diameter, the animals are randomized into 4 groups and treated daily by oral gavage. The animals are grouped as: Control group, LDM Topotecan group or LDM TP (1 mg/kg Topotecan), Pazopanib group or PZ (150 mg/kg Pazopanib) and combination group or TP + PZ (1 mg/kg Topotecan Hydrochloride + 150 mg/kg Pazopanib). To compare pulse Topotecan with LDM TP in KHOS osteosarcoma model, PZ is replaced by weekly oral dose of pulse Topotecan or Pulse TP (15 mg/kg Topotecan). The criteria for endpoint are tumor sizes exceeding 2.0 cm in diameter or animals showing signs of morbidity. The tumor sizes are measured on a daily basis until the endpoint or sacrifice. The long (D) and short diameters (d) are measured with calipers. Tumor volume (cm³) is calculated as V=0.5×D×d². When the endpoint is reached or at the end of the treatment, the animals are sacrificed by cervical dislocation.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang FL, et al. PLoS One. 2013 Nov 26;8(11):e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells. [Content Brief]

[2]. Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17(17):5656-67. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.1838 mL	10.9192 mL	21.8384 mL	54.5959 mL
	5 mM	0.4368 mL	2.1838 mL	4.3677 mL	10.9192 mL
	10 mM	0.2184 mL	1.0919 mL	2.1838 mL	5.4596 mL
	15 mM	0.1456 mL	0.7279 mL	1.4559 mL	3.6397 mL
	20 mM	0.1092 mL	0.5460 mL	1.0919 mL	2.7298 mL
	25 mM	0.0874 mL	0.4368 mL	0.8735 mL	2.1838 mL
	30 mM	0.0728 mL	0.3640 mL	0.7279 mL	1.8199 mL
	40 mM	0.0546 mL	0.2730 mL	0.5460 mL	1.3649 mL
	50 mM	0.0437 mL	0.2184 mL	0.4368 mL	1.0919 mL
	60 mM	0.0364 mL	0.1820 mL	0.3640 mL	0.9099 mL
DMSO	80 mM	0.0273 mL	0.1365 mL	0.2730 mL	0.6824 mL
DMSO	100 mM	0.0218 mL	0.1092 mL	0.2184 mL	0.5460 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Topotecan hydrochloride

40 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Topotecan hydrochloride

Publications Citing Use of MedChemExpress (MCE) Topotecan hydrochloride

Alle Topoisomerase Isoform-spezifische Produkte anzeigen